Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Sci Rep ; 13(1): 3626, 2023 03 03.
Article in English | MEDLINE | ID: mdl-36869231

ABSTRACT

Circulating tumor cells (CTC) have been studied in various solid tumors but clinical utility of CTC in small cell lung cancer (SCLC) remains unclear. The aim of the CTC-CPC study was to develop an EpCAM-independent CTC isolation method allowing isolation of a broader range of living CTC from SCLC and decipher their genomic and biological characteristics. CTC-CPC is a monocentric prospective non-interventional study including treatment-naïve newly diagnosed SCLC. CD56+ CTC were isolated from whole blood samples, at diagnosis and relapse after first-line treatment and submitted to whole-exome-sequencing (WES). Phenotypic study confirms tumor lineage and tumorigenic properties of isolated cells for the 4 patients analyzed with WES. WES of CD56+ CTC and matched tumor biopsy reveal genomic alteration frequently impaired in SCLC. At diagnosis CD56+ CTC were characterized by a high mutation load, a distinct mutational profile and a unique genomic signature, compared to match tumors biopsies. In addition to classical pathways altered in SCLC, we found new biological processes specifically affected in CD56+ CTC at diagnosis. High numeration of CD56+ CTC (> 7/ml) at diagnosis was associated with ES-SCLC. Comparing CD56+ CTC isolated at diagnosis and relapse, we identify differentially altered oncogenic pathways (e.g. DLL3 or MAPK pathway). We report a versatile method of CD56+ CTC detection in SCLC. Numeration of CD56+ CTC at diagnosis is correlated with disease extension. Isolated CD56+ CTC are tumorigenic and show a distinct mutational profile. We report a minimal gene set as a unique signature of CD56+ CTC and identify new affected biological pathways enriched in EpCAM-independent isolated CTC in SCLC.


Subject(s)
Lung Neoplasms , Neoplastic Cells, Circulating , Small Cell Lung Carcinoma , Humans , Epithelial Cell Adhesion Molecule , Clinical Relevance , Prospective Studies , Genomics , Carcinogenesis , Membrane Proteins , Intracellular Signaling Peptides and Proteins
2.
Br J Cancer ; 113(2): 336-44, 2015 Jul 14.
Article in English | MEDLINE | ID: mdl-26035699

ABSTRACT

BACKGROUND: The von Hippel-Lindau (VHL) gene encodes two mRNA variants. Variant 1 encodes two protein isoforms, pVHL213 and pVHL160, that have been extensively documented in the literature. Variant 2 is produced by alternative splicing of exon 2 and encodes a pVHL isoform of 172 amino acids with a theoretical molecular weight of 19 kDa (pVHL172), the expression of which has never been demonstrated so far due to the absence of suitable antibodies. METHODS: We have generated an anti-pVHL monoclonal antibody (JD-1956) using pVHL172 recombinant protein. We tested the antibody against exogenous or endogenous expressed proteins in different cell lines. We identified the pVHL172 using a silencing RNA strategy. The epitope of the antibody was mapped using a peptide array. RESULTS: We efficiently detected the three different isoforms of pVHL in cell lines and tumorigenic tissues by western blotting and immunohistochemistry and confirmed for the first time the endogenous expression of pVHL172. CONCLUSIONS: The endogenous expression of the three isoforms and particularly the pVHL172 has never been shown before due to a lack of a highly specific antibody since none of the available commercial antibodies distinguish the three isoforms of pVHL in cells or in both normal and cancerous human tissues. Evidence of pVHL172 expression emphasises the need to further study its implication in renal tumorigenesis and VHL disease.


Subject(s)
Genes, Tumor Suppressor , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Amino Acid Sequence , Antibody Specificity , Blotting, Western , Cell Line, Tumor , Humans , Immunohistochemistry , Molecular Sequence Data , Protein Isoforms/analysis , Protein Isoforms/chemistry , Protein Isoforms/genetics , Von Hippel-Lindau Tumor Suppressor Protein/analysis , Von Hippel-Lindau Tumor Suppressor Protein/chemistry
3.
Prog Urol ; 24(2): 73-9, 2014 Feb.
Article in French | MEDLINE | ID: mdl-24485075

ABSTRACT

INTRODUCTION: A controversy animates the literature on the potential role of the renin-angiotensin system (RAS) in tumorogenesis. The objective of this review was to determine the involvement of this pathway in cancer, and more specifically in urological cancers. MATERIAL AND METHOD: We made a systematic review of articles referenced in Pubmed, using the following keywords alone or combined: cancer, renin, angiotensin, VEGF, AT1R, antagonists of angiotensin-2 receptors, inhibitors of angiotensinogen converting. RESULTS: Many types of cancers overexpress AT1-R in their tumoral tissues (breast, stomach, bladder, astrocytoma, glioblastoma, ovary, uterus, pancreas, kidney, prostate, adrenal gland). Ang-II can induce VEGF-A expression and promote neoangiogenesis, but also can trigger different molecular pathways involved in cell proliferation or inhibit apoptosis. Several xenograft murin models demonstrated anti-tumoral efficacy of RAS blockers, alone or using combined therapies, targeting angiogenesis and slowing down tumor growth. Retrospective studies in patients have also revealed a better progression-free survival and a better response to therapies in those treated with RAS blockers. CONCLUSION: Many data seem to demonstrate the involvement of the RAS in carcinogenesis, as well as anti-tumoral effect of RAS blockers in addition to anti-cancer treatments. Clinical data are now expected to confirm these experimental findings.


Subject(s)
Renin-Angiotensin System/physiology , Urologic Neoplasms/etiology , Humans
5.
Int J Cancer ; 134(9): 2051-60, 2014 May 01.
Article in English | MEDLINE | ID: mdl-24136590

ABSTRACT

The partition-defective 3 (PAR-3) protein is implicated in the development and maintenance of cell polarity and is associated with proteins that mediate the changes in cytoskeleton organization required for cell polarity establishment. In this work, we used two original primary cell lines (R-180 and R-305) derived from clear cell Renal Cell Carcinoma (ccRCC) surgical specimens of a patient with unfavorable clinical course (R-180 cells) and a patient with favorable prognosis (R-305 cells) to identify genetic and molecular features that may explain the survival difference of the two patients. The cytogenetic analysis of these cell lines revealed that the PARD3 gene was amplified only in the R-180 cell line that was derived from an aggressive ccRCC. PARD3 gene amplification was associated with overexpression of the encoded protein and altered cytoskeleton organization. Consistently, PARD3 knockdown in R-180 cells restored the cytoskeleton organization and reduced cell migration in comparison to non-transfected cells. Immunohistochemical analysis of ccRCC samples from a cohort of 96 patients with a follow-up of 6 years revealed that PAR-3 overexpression was correlated with poor survival. Our results suggest that PAR-3 has a role in the clinical aggressiveness of ccRCC, possibly by promoting cell migration.


Subject(s)
Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Cell Cycle Proteins/biosynthesis , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Membrane Proteins/biosynthesis , Adaptor Proteins, Signal Transducing , Adult , Aged , Blotting, Western , Carcinoma, Renal Cell/mortality , Cell Line, Tumor , Cell Movement , Cytoskeleton/metabolism , Cytoskeleton/pathology , Female , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Kidney Neoplasms/mortality , Male , Middle Aged , Prognosis
6.
Prog Urol ; 21(12): 851-8, 2011 Nov.
Article in French | MEDLINE | ID: mdl-22035911

ABSTRACT

OBJECTIVE: To determine the prognostic significance of the neutrophil gelatinase-associated lipocalin (NGAL) and the matrix metalloproteinase 9 (MMP-9) in clear cell renal cell carcinoma (CCRCC). PATIENTS AND METHODS: NGAL and MMP-9 expression were quantified by immunohistochemistry in clear renal cell carcinoma tissues and in sera by Enzyme Linked Immunosorbent Assay (Elisa). Results were associated with clinicopathologic data. RESULTS: Seventy-four patients operated for CCRCC in Rennes between 2003 and 2009 were included. High concentrations of NGAL-MMP-9 complex in serum were associated with short progression free survival (PFS) (33.3 months versus 47.3 months, P=0.016) and poor overall survival (42.5 months versus 51.9 months, P<0.047). High NGAL concentrations in serum were also associated with shorter PFS (13.6 months versus 41.6 months, P=0.04). However, no NGAL expression was observed in renal tumor cells. Interestingly, NGAL was expressed by neutrophils infiltrating CCRCC and we showed that the density of NGAL expressing neutrophils was associated with pejorative PFS and survival (36.9months versus 56.1 months, P<0.006). CONCLUSION: In this study, we showed the pejorative significance of NGAL-MMP-9 complex and NGAL rates in serum of CCRCC. We also confirmed that density of NGAL expressing neutrophils in CCRCC was associated with poor outcome.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Renal Cell/enzymology , Kidney Neoplasms/enzymology , Lipocalins/blood , Matrix Metalloproteinase 9/blood , Proto-Oncogene Proteins/blood , Acute-Phase Proteins , Aged , Carcinoma, Renal Cell/blood , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Female , Humans , Kidney Neoplasms/blood , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Lipocalin-2 , Male , Middle Aged , Neoplasm Invasiveness , Predictive Value of Tests , Prognosis , Sensitivity and Specificity , Survival Analysis
7.
Br J Cancer ; 103(11): 1698-705, 2010 Nov 23.
Article in English | MEDLINE | ID: mdl-21102591

ABSTRACT

BACKGROUND: The growth factor Angiotensin-2 signals through Angiotensin receptor type 1 (AT1-R) in a broad range of cell types and tumours and through the type-2 receptor (AT2-R) in a more restricted group of cell types. Although numerous forms of cancer have been shown to overexpress AT1-R, expression of AT1-R and AT2-R by human renal clear-cell carcinoma (RCCC) is not well understood. In this study, the expression of both angiotensin receptors was quantified in a retrospective series of RCCC and correlated with prognostic factors. METHODS: Angiotensin receptor type 1 and AT2-R expressions were quantified on tumour tissues by immunohistochemistry (IHC), western blot and quantitative reverse transcriptase PCR (qRT-PCR). IHC results were correlated to Fuhrman's grade and patient progression-free survival (PFS). RESULTS: A total of 84 RCCC were analysed. By IHC, AT1-R and AT2-R were expressed to a greater level in high-grade tumours (AT1-R: P<0.001, AT2-R: P<0.001). Univariate analysis showed a correlation between PFS and AT1-R or AT2-R expression (P=0.001). By multivariate analysis, only AT2-R expression correlated with PFS (HR 1.021, P=0.006) and cancer stage (P<0.001). By western blot, AT1-R and AT1-R were also found to be overexpressed in higher Fuhrman's grade (P<0.01 and P=0.001 respectively). By qRT-PCR, AT1-R but not AT2-R mRNA were downregulated (P=0.001 and P=0.118, respectively). CONCLUSION: Our results show that AT1-R and AT2-R proteins are overexpressed in the most aggressive forms of RCCC and that AT2-R expression correlates with PFS. AT1-R or AT2-R blockage could, therefore, offer novel directions for anti-RCCC therapy.


Subject(s)
Carcinoma, Renal Cell/mortality , Kidney Neoplasms/mortality , Receptor, Angiotensin, Type 1/analysis , Receptor, Angiotensin, Type 2/analysis , Angiotensin Receptor Antagonists/therapeutic use , Blotting, Western , Carcinoma, Renal Cell/chemistry , Disease-Free Survival , Humans , Immunohistochemistry , Kidney Neoplasms/chemistry , Multivariate Analysis , Prognosis , Reverse Transcriptase Polymerase Chain Reaction
8.
Br J Cancer ; 101(8): 1417-24, 2009 Oct 20.
Article in English | MEDLINE | ID: mdl-19755989

ABSTRACT

BACKGROUND: The von Hippel-Lindau gene (VHL) alteration, a common event in sporadic clear-cell renal-cell carcinoma (CCRCC), leads to highly vascularised tumours. Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis, but the prognostic significance of both VHL inactivation and VEGF expression remain controversial. The aims of this study were to analyse the relationship between VHL genetic and epigenetic alterations, VHL expression and VEGF tumour or plasma expression, and to analyse their respective prognostic value in patients with CCRCC. METHODS: A total of 102 patients with CCRCC were prospectively analysed. Alterations in VHL were determined by sequencing, Multiplex Ligation-dependent Probe Amplification (MLPA) and methylation-specific MLPA. Expression of pVHL and VEGF was determined by immunohistochemistry. Plasma VEGF was measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: VHL mutation, deletion and promoter methylation were identified in 70, 76 and 14 cases, respectively. Overall, at least one VHL-gene alteration occurred in 91 cases (89.2%). Both VEGF tumour and plasma expression appeared to be decreased in case of VHL alteration. Median progression-free survival and CCRCC-specific survival were significantly reduced in patients with wild-type VHL or altered VHL and high VEGF expression, which, therefore, represent two markers of tumour aggressiveness in CCRCC. CONCLUSION: Stratifying CCRCCs according to VHL and VEGF status may help tailor therapeutic strategy.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Vascular Endothelial Growth Factor A/genetics , Von Hippel-Lindau Tumor Suppressor Protein/genetics , Adult , Aged , Aged, 80 and over , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , DNA Methylation , Female , Humans , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Male , Middle Aged , Mutation , Vascular Endothelial Growth Factor A/blood
9.
Oncogene ; 27(51): 6590-5, 2008 Nov 20.
Article in English | MEDLINE | ID: mdl-18679423

ABSTRACT

Cisplatin is one of the most effectively used chemotherapeutic agents for cancer treatment. However, in humans, important cytotoxic side effects are observed including dose-limiting renal damage and profound gastrointestinal symptomatology. The toxic responses to cisplatin in mice are similar to those in human patients. Here, we evaluated whether the acid sphingomyelinase (Asm) mediates at least some of the toxic in vivo effects of cisplatin. To this end, we determined the toxic effects of a single intraperitoneal dose of cisplatin (27 mg/kg) in wild type (Asm(+/+)) and Asm-deficient mice (Asm(-/-)). Tissue injury and apoptosis were determined histologically on hematoxylin-eosin and TUNEL (terminal deoxynucleotidyl transferase (TdT)-mediated nick end labeling) stainings 3, 12, 36 and 72 h after treatment. Our results revealed severe toxicity of cisplatin in Asm(+/+) mice with increased numbers of apoptotic cells in the thymus and small intestine. In marked contrast, Asm(-/-) mice were resistant to cisplatin and no apoptosis was observed in these organs after treatment. Moreover, cisplatin treatment primarily triggered apoptosis of endothelial cells in microvessels of intestine and thymus, an effect that was absent in mice lacking Asm. The data thus suggest that at least some toxic effects of cisplatin are mediated by the Asm in vivo resulting in early death of endothelial cells and consecutive organ damage.


Subject(s)
Antineoplastic Agents/adverse effects , Cisplatin/adverse effects , Cytoprotection/genetics , Gastrointestinal Diseases/chemically induced , Gastrointestinal Tract/drug effects , Sphingomyelin Phosphodiesterase/genetics , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis/genetics , Cisplatin/pharmacology , Cytoprotection/drug effects , Drug Evaluation, Preclinical , Gastrointestinal Diseases/pathology , Gastrointestinal Tract/metabolism , Gastrointestinal Tract/pathology , Genes, p53 , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Mice , Mice, Knockout , Sphingomyelin Phosphodiesterase/physiology
10.
Nouv Presse Med ; 7(13): 1109-11, 1978 Apr 01.
Article in French | MEDLINE | ID: mdl-662627

ABSTRACT

This technique of revascularisation of the digestive arteries is suggested when the infrarenal aorta cannot be used. The hepatic artery is reimplanted in the coeliac region. The vein graft is passed in the root of the transverse mesocolon and anastomosed with the superior mesenteric artery. The subclavian artery, frequently used in the revascularisation of the neck vessels, was felt to be preferable to the axillary artery. Passage of the graft retrosternally avoids any kinking or compression in the abdominal wall. The patient's own saphenous vein is the most suitable material. If this is not possible, a varicosity preserved by cold was felt to be preferable to a dacron tube.


Subject(s)
Aortic Diseases/surgery , Assisted Circulation/methods , Digestive System/blood supply , Mesenteric Arteries/surgery , Aged , Aorta, Abdominal , Aortic Diseases/complications , Arterial Occlusive Diseases/surgery , Celiac Artery/surgery , Female , Hepatic Artery/surgery , Humans , Subclavian Vein/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...